Anlotinib plus immunotherapy and chemoradiotherapy for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests whether adding an investigational drug (anlotinib) to standard chemotherapy and radiation, along with immunotherapy, can better control high-risk nasopharyngeal cancer. It aims to see if this combination reduces the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with nasopharyngeal cancer (a type of cancer in the back of the nose and throat) that is non-keratinizing, meaning it has a specific cell type.
- Your cancer is at a high-risk stage, such as T4N2 or T1-4N3 (your doctor can confirm this).
- Your overall health is good, with normal blood counts, liver, kidney, and heart function.
- If you are of childbearing age, you must agree to use effective birth control during the study and for 1 year after the last dose of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.